Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Bronstein, Gewirtz & Grossman, is investigating potential claims against Syros Pharmaceuticals, Inc. (NASDAQ:SYRS). The investigation follows Syros' announcement on August 12, 2024, that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial for acute myeloid leukemia (AML) treatment. This decision was based on a prespecified interim analysis indicating a low probability of success in demonstrating superiority at the final analysis.
Investors who purchased Syros securities are encouraged to participate in the investigation. The law firm is offering its services on a contingency fee basis, meaning fees will only be charged if the case is successful. Bronstein, Gewirtz & Grossman, has a track record of recovering significant sums for investors in securities fraud class actions and shareholder derivative suits.
Bronstein, Gewirtz & Grossman sta indagando su potenziali richieste contro Syros Pharmaceuticals, Inc. (NASDAQ:SYRS). L'investigazione segue l'annuncio di Syros del 12 agosto 2024, secondo cui sospenderà l'arruolamento nel trial clinico di Fase 2 SELECT-AML-1 per il trattamento della leucemia mieloide acuta (AML). Questa decisione è stata basata su un'analisi intermedia predefinita che indicava una bassa probabilità di successo nel dimostrare la superiorità all'analisi finale.
Gli investitori che hanno acquistato titoli Syros sono incoraggiati a partecipare all'indagine. Lo studio legale offre i suoi servizi su base contingente, il che significa che le spese verranno addebitate solo se il caso avrà successo. Bronstein, Gewirtz & Grossman ha una comprovata esperienza nel recupero di somme significative per gli investitori in azioni collettive per frode sui titoli e cause derivative degli azionisti.
Bronstein, Gewirtz & Grossman está investigando posibles reclamaciones contra Syros Pharmaceuticals, Inc. (NASDAQ:SYRS). La investigación sigue el anuncio de Syros del 12 de agosto de 2024, que interrumpirá la inscripción en el ensayo clínico de Fase 2 SELECT-AML-1 para el tratamiento de la leucemia mieloide aguda (AML). Esta decisión se basó en un análisis interino predefinido que indica una baja probabilidad de éxito para demostrar superioridad en el análisis final.
Se anima a los inversores que compraron valores de Syros a participar en la investigación. El bufete de abogados ofrece sus servicios en una base de honorarios de contingencia, lo que significa que solo se cobrarán tarifas si el caso tiene éxito. Bronstein, Gewirtz & Grossman tiene un historial de recuperación de sumas significativas para los inversores en acciones colectivas por fraude de valores y demandas derivadas de accionistas.
Bronstein, Gewirtz & Grossman은 Syros Pharmaceuticals, Inc. (NASDAQ:SYRS)에 대한 잠재적 청구를 조사하고 있습니다. 이번 조사는 Syros가 2024년 8월 12일에 발표한, 급성 골수성 백혈병(AML) 치료를 위한 SELECT-AML-1 2상 임상 시험의 참가자 모집을 중단하겠다는 결정에 따른 것입니다. 이 결정은 최종 분석에서 우위성을 입증할 낮은 성공 확률을 나타내는 사전 정의된 중간 분석을 기반으로 했습니다.
Syros의 증권을 구매한 투자자들은 조사에 참여할 것을 권장합니다. 법률사무소는 성과 기반 수수료 제도를 제공하며, 사건이 성공적인 경우에만 수수료가 부과됩니다. Bronstein, Gewirtz & Grossman은 증권 사기 집단 소송과 주주 파생 소송에서 투자자들에게 상당한 금액을 회수한 경력があります.
Bronstein, Gewirtz & Grossman est en train d'examiner des réclamations potentielles contre Syros Pharmaceuticals, Inc. (NASDAQ:SYRS). Cette enquête fait suite à l'annonce de Syros le 12 août 2024, selon laquelle elle cessera l'inscription à l'essai clinique de Phase 2 SELECT-AML-1 pour le traitement de la leucémie myéloïde aiguë (AML). Cette décision a été fondée sur une analyse intermédiaire prédéfinie indiquant une faible probabilité de succès dans la démonstration de supériorité lors de l'analyse finale.
Les investisseurs ayant acheté des titres Syros sont encouragés à participer à l'enquête. Le cabinet d'avocats offre ses services sur une base de success fee, ce qui signifie que les frais ne seront facturés que si l'affaire est couronnée de succès. Bronstein, Gewirtz & Grossman a fait ses preuves en récupérant d'importantes sommes pour les investisseurs dans des actions collectives pour fraude sur titres et des actions dérivées de shareholders.
Bronstein, Gewirtz & Grossman untersucht potenzielle Ansprüche gegen Syros Pharmaceuticals, Inc. (NASDAQ:SYRS). Die Untersuchung folgt auf die Ankündigung von Syros am 12. August 2024, dass man die Einschreibung einstellen werde für die SELECT-AML-1 Phase-2-Studie zur Behandlung der akuten myeloischen Leukämie (AML). Diese Entscheidung basierte auf einer vorab festgelegten Zwischenanalyse, die eine geringe Erfolgswahrscheinlichkeit für den Nachweis der Überlegenheit bei der Abschlussanalyse anzeigte.
Investoren, die Wertpapiere von Syros erworben haben, werden ermutigt, an der Untersuchung teilzunehmen. Die Kanzlei bietet ihre Dienste auf Erfolgsbasis an, was bedeutet, dass Gebühren nur anfallen, wenn der Fall erfolgreich ist. Bronstein, Gewirtz & Grossman hat eine Erfolgsbilanz bei der Rückgewinnung erheblicher Beträge für Investoren in Sammelklagen wegen Wertpapierbetrugs und in geschäftlichen Derivatsklagen.
- None.
- Discontinuation of SELECT-AML-1 Phase 2 clinical trial enrollment
- Low probability of success in demonstrating treatment superiority
- Potential legal claims against the company
- Possible negative impact on investor confidence and stock value
Insights
This investigation by Bronstein, Gewirtz & Grossman, into Syros Pharmaceuticals raises significant legal and financial concerns for investors. The discontinuation of the SELECT-AML-1 Phase 2 clinical trial is a major setback for the company's drug development pipeline. This could potentially lead to securities fraud claims if it's found that Syros withheld or misrepresented material information about the trial's prospects.
Investors should be aware that class action lawsuits in biotech often hinge on whether companies adequately disclosed risks associated with clinical trials. The key question here will be if Syros properly communicated the likelihood of trial failure to shareholders. If not, this could result in substantial financial liabilities for the company and possible regulatory scrutiny from the SEC.
The discontinuation of the SELECT-AML-1 Phase 2 trial is a significant blow to Syros's oncology pipeline. This study was evaluating a triplet therapy for acute myeloid leukemia (AML), a challenging cancer to treat. The decision to halt enrollment based on interim analysis suggests the treatment's efficacy fell short of expectations.
This outcome raises questions about the viability of tamibarotene in combination therapies for AML. It also highlights the inherent risks in oncology drug development, particularly in targeting complex diseases like AML. For Syros, this setback likely means a substantial delay in bringing a potential AML treatment to market, if at all, which could impact their competitive position in the hematologic cancer space.
This news is likely to have a significant negative impact on Syros Pharmaceuticals' stock price and financial outlook. The discontinuation of a Phase 2 trial represents the loss of a potential future revenue stream and raises questions about the company's R&D productivity. Investors may reassess Syros's pipeline value and cash burn rate.
Moreover, the potential for legal action could result in additional financial burdens and reputational damage. This may affect Syros's ability to raise capital in the future, which is important for biotech companies with no approved products. Shareholders should closely monitor the company's cash position and any updates on its remaining pipeline assets to gauge the long-term financial health of Syros.
NEW YORK CITY, NY / ACCESSWIRE / August 28, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS). Investors who purchased Syros securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SYRS.
Investigation Details
On August 12, 2024, Syros issued a press release "announcing that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial evaluating the triplet regimen of tamibarotene in combination with venetoclax and azacitidine compared to the doublet regimen of venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression." According to the Company, the "decision is based on the results of a prespecified interim analysis of the trial," and its analysis that "the probability for success . . . to demonstrate superiority at the final analysis . . . was considered low."
What's Next?
If you are aware of any facts relating to this investigation or purchased Syros securities, you can assist this investigation by visiting the firm's site: bgandg.com/SYRS. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller,
332-239-2660 | info@bgandg.com
SOURCE: Bronstein, Gewirtz and Grossman, LLC
View the original press release on accesswire.com
FAQ
What is the reason for the investigation into Syros Pharmaceuticals (SYRS)?
When did Syros Pharmaceuticals (SYRS) announce the discontinuation of the SELECT-AML-1 trial?
What was the SELECT-AML-1 Phase 2 clinical trial by Syros Pharmaceuticals (SYRS) investigating?
How can investors participate in the investigation of Syros Pharmaceuticals (SYRS)?
